Variant Interpretation for Dilated Cardiomyopathy
- 1 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 13 (2) , e002480
Abstract
Background: The hypothesis of the Dilated Cardiomyopathy Precision Medicine Study is that most dilated cardiomyopathy has a genetic basis. The study returns results to probands and, when indicated, to relatives. While both the American College of Medical Genetics and Genomics/Association for Molecular Pathology and ClinGen’s MYH7 -cardiomyopathy specifications provide relevant guidance for variant interpretation, further gene- and disease-specific considerations were required for dilated cardiomyopathy. To this end, we tailored the ClinGen MYH7 -cardiomyopathy variant interpretation framework; the specifications implemented for the study are presented here. Methods: Modifications were created and approved by an external Variant Adjudication Oversight Committee. After a pilot using 81 probands, further adjustments were made, resulting in 27 criteria (9 modifications of the ClinGen MYH7 framework and reintroduction of 2 American College of Medical Genetics and Genomics/Association of Molecular Pathology criteria that were deemed not applicable by the ClinGen MYH7 working group). Results: These criteria were applied to 2059 variants in a test set of 97 probands. Variants were classified as benign (n=1702), likely benign (n=33), uncertain significance (n=71), likely pathogenic (likely pathogenic; n=12), and pathogenic (P; n=3). Only 2/15 likely pathogenic/P variants were identified in Non-Hispanic African ancestry probands. Conclusions: We tailored the ClinGen MYH7 criteria for our study. Our preliminary data show that 15/97 (15.5%) probands have likely pathogenic/P variants, most of which were identified in probands of Non-Hispanic European ancestry. We anticipate continued evolution of our approach, one that will be informed by new insights on variant interpretation and a greater understanding of the genetic architecture of dilated cardiomyopathy. Clinical Trial Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03037632Keywords
This publication has 40 references indexed in Scilit:
- Lethal, Hereditary Mutants of Phospholamban Elude Phosphorylation by Protein Kinase AJournal of Biological Chemistry, 2012
- A Proton Leak Current through the Cardiac Sodium Channel Is Linked to Mixed Arrhythmia and the Dilated Cardiomyopathy PhenotypePLOS ONE, 2012
- Truncations of Titin Causing Dilated CardiomyopathyNew England Journal of Medicine, 2012
- Brugada Syndrome 2012Circulation Journal, 2012
- Genome-wide Studies of Copy Number Variation and Exome Sequencing Identify Rare Variants in BAG3 as a Cause of Dilated CardiomyopathyThe American Journal of Human Genetics, 2011
- PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: Summary of the literature and implications for genetic testingAmerican Heart Journal, 2011
- Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionalsGenetics in Medicine, 2010
- An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testingHeart Rhythm, 2010
- ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007Genetics in Medicine, 2008
- Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathyJournal of Molecular and Cellular Cardiology, 2007